Preliminary data on microRNA expression profiles in a group of South African patients diagnosed with chronic myeloid leukaemia

Prinsloo,Andrea; Pool,Roger; Van Niekerk,Chantal

doi:10.3892/mco.2017.1319

Preliminary data on microRNA expression profiles in a group of South African patients diagnosed with chronic myeloid leukaemia

Authors:
- Andrea Prinsloo
- Roger Pool
- Chantal Van Niekerk
View Affiliations

Affiliations: Department of Haematology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of The National Health Laboratory Service, Pretoria, Gauteng, South Africa, Department of Chemical Pathology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of The National Health Laboratory Service, Pretoria, Gauteng, South Africa
Published online on: July 13, 2017 https://doi.org/10.3892/mco.2017.1319
Pages: 386-390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Micro‑ribonucleic acids (miRNAs) are small functional non‑coding RNAs that downregulate gene expression at the post‑transcriptional level. Abnormal expression of specific miRNAs has been recorded in chronic lymphocytic leukaemia, other non‑Hodgkin B‑cell lymphomas, lung cancer and chronic myeloid leukaemia (CML). The aim of this study was to compare miRNA expression profiles among patients with newly diagnosed CML, those on established therapy with imatinib mesylate, and healthy individuals. The expression of 88 miRNAs was evaluated in a total of nine samples divided into three groups: Group 1 comprised three samples collected from newly diagnosed CML patients; group 2 consisted of three samples collected from patients on therapy; the remaining three samples were collected from healthy volunteers (control group). Total RNA was extracted from whole blood and reverse transcriptase quantitative polymerase chain reaction (RT‑qPCR) was performed on the LightCycler® 480 platform using Human Serum & Plasma miRNA PCR Arrays. In group 1, only SNORD44 was downregulated, while hsa‑miR‑372 and hsa‑miR‑375 were found to be significantly upregulated compared with the control group. By contrast, 49 miRNAs were significantly upregulated in group 2 compared with the control group. miRNAs hsa‑miR‑106b, hsa‑miR‑21, hsa‑miR‑221, hsa‑miR‑10a, hsa‑miR‑193a‑5p and hsa‑miR‑30e were expressed in group 2. Therefore, miRNA expression profiles differed between the two patient groups.

View Figures

View References

1	Liesveld JL and Lichtman MA: Chronic Myelogenous Leukaemia and related disordersWilliams Hematology. Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U and Prchal JT: Mcraw-Hill; New York: pp. 1331–1336. 2010
2	Schüler F and Dölken G: Detection and monitoring of minimal residual disease by quantitative real-time PCR. Clin Chim Acta. 363:147–156. 2006. View Article : Google Scholar : PubMed/NCBI
3	Stenthoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL and Hokland P: Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol. 67:302–308. 2001. View Article : Google Scholar : PubMed/NCBI
4	San J, osé-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P, Calasanz MJ, Prósper F and Agirre X: MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 8:692009. View Article : Google Scholar : PubMed/NCBI
5	Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger M, Silver RT, Goldman JM, Stone RM, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hoffbrand AV and Moss PAH: Chronic Myeloid LeukaemiaEssential Haematology. Wiley-Blackwell; United Kingdom: pp. 1962011
7	Yeung ML, Bennasser Y and Jeang KT: miRNAs in the biology of cancers and viral infections. Curr Med Chem. 14:191–197. 2007. View Article : Google Scholar : PubMed/NCBI
8	Georgantas RW III, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, Croce CM and Civin CI: CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc Natl Acad Sci USA. 104:2750–2755. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lawrie CH: MicroRNAs and haematology: Small molecules, big function. Br J Haematol. 137:503–512. 2007. View Article : Google Scholar : PubMed/NCBI
10	Krichevsky AM, King KS, Donahue CP, Khrapko K and Kosik KS: A microRNA array reveals extensive regulation of microRNAs during brain development. RNA. 9:1274–1281. 2003. View Article : Google Scholar : PubMed/NCBI
11	Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic P, Constantine-Paton M and Horvitz HR: Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 5:R682004. View Article : Google Scholar : PubMed/NCBI
12	Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M and Scherr M: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 109:4399–4405. 2007. View Article : Google Scholar : PubMed/NCBI
13	He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
14	Gordon JE, Wong JJ and Rasko JE: MicroRNAs in myeloid malignancies. Brit J of Haematol. 162:162–176. 2013. View Article : Google Scholar
15	Yeh CH, Moles R and Nicot C: Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 15:372016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI
18	Cummins JM and Velculescu VE: Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 25:6220–6227. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wu W, Sun M, Zou GM and Chen J: MicroRNA and cancer: Current status and prospective. Int J Cancer. 120:953–960. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP Jr, Sloand EM, Kajigaya S and Young NS: Hematopoietic-specific microRNA expression in human cells. Leuk Res. 30:643–647. 2006. View Article : Google Scholar : PubMed/NCBI